MRK.DE - MERCK Kommanditgesellschaft auf Aktien
| Previous Close | 96.00 |
| Open | 95.96 |
| Bid | 0.00 x 6700 |
| Ask | 0.00 x 11200 |
| Day's Range | 95.46 - 96.50 |
| 52 Week Range | 74.54 - 100.20 |
| Volume | 387,634 |
| Avg. Volume | 460,306 |
| Market Cap | 41.688B |
| Beta (3Y Monthly) | 0.30 |
| PE Ratio (TTM) | 21.63 |
| EPS (TTM) | 4.45 |
| Earnings Date | Mar 7, 2019 |
| Forward Dividend & Yield | 1.25 (1.29%) |
| Ex-Dividend Date | 2018-04-30 |
| 1y Target Est | N/A |
- PR Newswire•6 days ago
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for UK-based media DARMSTADT, Germany and NEW YORK , Feb. 16, 2019 /PRNewswire/ -- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 ...
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of MRK.DE earnings conference call or presentation 14-Nov-18 1:00pm GMT
Q3 2018 Merck KGaA Earnings Call
Motley Fool•16 days agoGlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript
GSK earnings call for the period ending December 31, 2018.
Reuters•17 days agoGSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy
GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could also get up to a further 2.9 billion euros, depending on commercial milestones, for a total deal value of as much as 3.7 billion euros.
- PR Newswire•29 days ago
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
DARMSTADT, Germany , January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease ...
- Reuters•last month
BRIEF-Merck KGaA, Tencent Announce Collaboration On Digital Health Services In China
Jan 23 (Reuters) - Merck Kgaa: * MERCK AND TENCENT ANNOUNCE COLLABORATION ON INTELLIGENT DIGITAL HEALTHCARE SERVICES IN CHINA * COLLABORATION WILL PRIMARILY FOCUS ON INCREASING PUBLIC DISEASE AWARENESS ...
- Reuters•last month
European nations weigh impact of Brexit on drug supplies
FRANKFURT/DUBLIN, Jan 15 (Reuters) - Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal. Irish Prime Minister Leo Varadkar said a working group of health officials meeting weekly for the last two years had drawn up the watch list, but advised against stockpiling. "It is a really important message that I want to deliver to people in Ireland today, both to patients and pharmacists, that there is no need to stockpile medicines," Health Minister Simon Harris said at a news conference, warning that such action could inadvertently disturb the supply chain.
- Reuters•2 months ago
Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study
Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment to, platinum-based chemotherapy could not achieve the primary goal of progression-fee survival in patients. Last year, Bavencio, or avelumab, failed to prolong lives in a separate trial to evaluate the immunotherapy in gastric cancer patients.
- PR Newswire•2 months ago
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
DARMSTADT, Germany , and NEW YORK , December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that data from a planned ...
- PR Newswire•2 months ago
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
DARMSTADT, Germany , December 20, 2018 /PRNewswire/ -- Not intended for UK-based media Agreement enables Merck KGaA, Darmstadt, Germany , to maintain an investment in the rapidly advancing oncology field ...
- Simply Wall St.•2 months ago
What Kind Of Shareholder Appears On The MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) Shareholder Register?
The big shareholder groups in MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
- PR Newswire•2 months ago
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer (BTC). The FDA orphan drug designation follows the recent presentation of the first clinical data for M7824 in BTC at the European Society of Medical Oncology (ESMO) congress in October.
- PR Newswire•3 months ago
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has entered into a licensing agreement with Cyclica Inc. for the use of Ligand Express®, a cloud-based in silico proteome screening platform. Ligand Express® is a structure-based and artificial intelligence (AI) augmented proteome screening platform that is being used to uncover novel targets that are modelled to interact with a small molecule.
- Bloomberg•3 months ago
Merck KGaA Partners With Startup for Image Tagging Software
“In health care alone, there are massive amounts of unstructured data generated every day in labs,” Michael Vande Vrede, head of digital products at Merck KGaA, said Tuesday at the conference on Neural Information Processing Systems (NeurIPS) in Montreal, where the two companies announced their collaboration. V7 has created software called Graphotate that makes it easier and faster to annotate scientific imagers and videos.
- Reuters•3 months ago
Big pharma leaves big gaps: drugmakers urged to do more for poor
Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday. The non-profit Access to Medicine Foundation (AMF) found companies overall were doing more than in the past to reach under-served populations, for example by setting lower prices for some drugs and improving transparency surrounding patents. What is more, research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.
- Reuters•3 months ago
UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck
Palantir Technologies Inc will set up a cancer data analytics joint venture with German lab supplies company Merck KGaA, as the U.S. analytics and security firm makes further inroads into health care. The new U.S.-based venture, called Syntropy, will offer cancer data analytics tools to research centres, combining Palantir's Foundry data platform with the customer knowledge of Merck's Life Science business, known as MilliporeSigma in North America, the companies said in a statement on Monday.
- PR Newswire•3 months ago
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
DARMSTADT, Germany and NEW YORK , November 19, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN ...
- Simply Wall St.•3 months ago
Taking A Look At MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
- Simply Wall St.•4 months ago
How Should Investors React To MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) CEO Pay?
In 2016 Stefan Oschmann was appointed CEO of MERCK Kommanditgesellschaft auf Aktien (FRA:MRK). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big Read More...
- Reuters•4 months ago
Merck KGaA says might strike partnership deal this year
German drugmaker Merck KGaA might agree partnership deals to jointly develop two of its most promising experimental medicines with a rival as early as this year, but more likely in 2019, its drug research and development chief said on Sunday. "It's possible even as early as the end of the year but that's really a stretch - or sometime in 2019," Luciano Rossetti told Reuters at the annual congress of the European Society for Medical Oncology in Munich on Sunday. Merck has a promising drug pipeline for the first time in several years but a decline in operating profit at its high-tech chemicals division has forced it to look into new ways to finance pharmaceutical development.
- PR Newswire•4 months ago
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the presentation of new data for cladribine tablets at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany. The data presented at ECTRIMS 2018 build on the existing real-world and clinical evidence around the safety and efficacy of cladribine tablets and reaffirm the benefit-risk profile of the oral treatment which is taken for a maximum of 20 days over two years.
- PR Newswire•5 months ago
Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Not intended for distribution in the U.K. ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1): 1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET ...
